Features Screener Stocks Charts
Sign In Sign Up

Opto Circuits (I) Ltd. Stock Valuation

NSE:OPTOCIRCUI | PHARMACEUTICALS

Share Price vs Book Value

10-year trend comparing market price with book value per share

FY 2011 - FY 2020

Opto Circuits (I) Ltd. Share Price vs Book Value — What It Means

Book Value Per Share (BVPS) represents the net asset value per share from the balance sheet — what shareholders would theoretically receive per share on liquidation. When Opto Circuits (I) Ltd.'s share price trades above book value (P/B > 1), the market is pricing in growth, earnings power, or intangible assets beyond what the balance sheet shows. A P/B below 1 may signal undervaluation or fundamental concerns. Compare the gap between share price and BVPS over time to assess whether the stock is trading at a premium or discount.

Market Metrics

Key market metrics for Opto Circuits (I) Ltd. (OPTOCIRCUI) listed on NSE. For pharmaceuticals sector companies, these metrics provide a snapshot of Opto Circuits (I) Ltd.'s market valuation and enterprise value, essential for comparing against intrinsic value estimates.

Share Price
₹1.80
May 23, 2022
Market Cap
₹0.54B
0.30B shares
Enterprise Value
₹10.38B
Market Cap + Net Debt

Stock Valuation Models for Opto Circuits (I) Ltd. (OPTOCIRCUI)

We analyze Opto Circuits (I) Ltd. using multiple valuation models appropriate for PHARMACEUTICALS companies. For PHARMACEUTICALS companies, we use P/E Ratio Analysis, Discounted Cash Flow (DCF), and EPS Growth Valuation to determine fair value estimates for Opto Circuits (I) Ltd. stock.

Current PE Ratio & Historical PE Ratio - Opto Circuits (I) Ltd.

10-year Price-to-Earnings ratio trend

Apr 2011 - May 2022

What Does Opto Circuits (I) Ltd.'s PE Ratio Tell Investors?

The P/E ratio measures how much investors pay for each rupee of earnings (Share Price / EPS). A higher PE suggests the market expects strong future growth, while a lower PE may indicate undervaluation or slower growth prospects. Compare Opto Circuits (I) Ltd.'s current PE against its historical median and PHARMACEUTICALS peers to gauge whether the stock is trading at a premium or discount relative to its earnings.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2020